4-O-(1,2-dioxa-8-azaspiro[4.5]decan-8-yl) 1-O-methyl (E)-2-ethylbut-2-enedioate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 4-O-(1,2-dioxa-8-azaspiro[4.5]decan-8-yl) 1-O-methyl (E)-2-ethylbut-2-enedioate
• 化学式: C₁₄H₂₁NO₆
• 分子量: 299.32
• InChiKey: HTDWTIDDUQQTOK-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  74.3
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF<br/>[FR] PROCÉDÉS D'UTILISATION DE FUMARATE DE MONOMÉTHYLE ET DE PROMÉDICAMENTS DE CELUI-CI
  申请人：XENOPORT INC

  公开号：WO2016182898A1

  公开（公告）日：2016-11-17

  Methods of therapeutic treatment of diseases such as certain cancers and liver diseases using monoalkyl fumarate prodrugs are disclosed.
• [EN] FUMARATE ESTER DOSAGE FORMS<br/>[FR] FORMES POSOLOGIQUES D'ESTER DE FUMARATE
  申请人：BANNER LIFE SCIENCES LLC

  公开号：WO2017040272A1

  公开（公告）日：2017-03-09

  Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.